Pacli-One 30/Pacli-One 100 Drug Interactions

The recommended regimen of Paclitaxel administration of primary treatment of ovarian carcinoma is for Paclitaxel to be given before cisplatin. When Paclitaxel is given before cisplatin, the safety profile of Paclitaxel is consistent with that reported for single agent use. When Paclitaxel was given after cisplatin, patients showed a more profound myelosuppression and an approximately 20% decrease in Paclitaxel clearance.
Medications concomitantly administered with Paclitaxel (e.g., corticosteroids, antihistamines, and H antagonists) did not appear to interact adversely; however, possible interactions of Paclitaxel with concomitantly administered medications have not been formally investigated. The metabolism of Paclitaxel is catalysed by cytochrome P450 isoenzymes CYP2C8 and CYP3A4. In the absence of formal clinical drug interaction studies, caution should be exercised when administering Paclitaxel concomitantly with known substrates or inhibitors of these isoenzymes.